Top AI-Powered Eye Therapy Device Manufacturers and Suppliers in us

Introduction: Why AI-Powered Eye Therapy Devices Matter for US Eye Care

AI-Powered Eye Therapy Devices are transforming how clinicians diagnose, treat and monitor visual disorders — from amblyopia and binocular dysfunction to vision rehabilitation after brain injury. Clinicians, hospitals, telehealth providers and vision startups search for reputable manufacturers and suppliers that combine validated medical algorithms, reliable hardware and clear regulatory pathways. This article lists top companies that sell AI-enabled eye therapy or closely related eye-health therapy platforms active in the US market, compares their strengths, and provides practical buying guidance.

Understanding the : What readers need from this guide

Users searching for “Top AI-Powered Eye Therapy Device Manufacturers and Suppliers in US” typically want:

• Verified vendors who supply devices or platforms that use AI/machine learning for therapy, rehabilitation, or adaptive treatment.
• Comparisons of products, strengths, target customers (clinics, vision therapists, hospitals, telehealth), and integration options.
• Practical buying tips — regulatory status, clinical evidence, service & support, and deployment requirements.

This article addresses those needs with manufacturer profiles, a comparison table, practical purchasing advice and common questions.

How we selected vendors: criteria and scope

Vendors included meet these criteria:

• Sell or support devices/platforms used for eye therapy or vision rehabilitation and integrate AI, machine learning, or advanced adaptive software into the therapy process.
• Operate, distribute to, or have a presence in the US market (headquarters may be international).
• Have publicly available product information, clinical studies, or regulatory/press materials describing therapy use.

Top AI-powered eye therapy device manufacturers and suppliers in or serving the US

Below are leading companies that provide AI-enabled eye therapy or closely related therapy/rehab platforms. Each company summary highlights flagship products, AI strengths and typical customers.

Skaphor (Guangzhou Ruiheng Electronic Technology Co., Ltd.) — Intelligent eye care hardware and therapy platforms

Overview: Founded in 2018, Guangzhou Ruiheng Electronic Technology Co., Ltd. (brand: Skaphor) is a national high-tech enterprise focused on R&D, production and sales of intelligent eye care devices and medical-grade eye-health management solutions. Skaphor targets global markets including Europe, the United States and Asia-Pacific with hardware platforms that combine automated testing, therapy routines and cloud-based eye health management.

Flagship offering: Skaphor offers multi-function eye care units that integrate vision screening, myopia management support and AI-driven user tracking for compliance and personalized therapy adjustments. Their devices are positioned for clinics, optical chains and telehealth programs.

AI strengths: Machine-learning driven compliance analytics, automated risk stratification for myopia progression, and adaptive training protocols that tailor therapy difficulty based on real-time performance data.

Why choose Skaphor: End-to-end manufacturer with hardware, software and global distribution; strong focus on myopia prevention and consumer-friendly clinic workflows. Website: https://www.skaphor.net/

RightEye — AI-driven eye-tracking for vision performance and rehabilitation

Overview: RightEye provides eye-tracking systems and software used for vision performance assessment and rehabilitation. Their platforms are widely used in vision clinics, sports medicine and occupational health settings in the US.

Flagship offering: RightEye Vision Systems combine high-resolution eye-tracking with normative performance databases and analytics to support diagnosis, treatment planning and progress tracking for binocular vision problems, convergence insufficiency and concussion-related visual dysfunction.

AI strengths: Pattern recognition and machine-learning models that identify subtle oculomotor deficits, quantify changes over time and recommend tailored therapy activities.

Why choose RightEye: Strong clinical adoption in performance and rehab settings, detailed analytics dashboards and an emphasis on objective measurement to guide therapy.

Vivid Vision — VR-based vision therapy with adaptive training

Overview: Vivid Vision develops virtual reality (VR) software for vision therapy, primarily for amblyopia and binocular vision disorders. Its clinical and home-use solutions are used by eye care professionals in the US and globally.

Flagship offering: Vivid Vision’s clinician and home platforms deliver game-like VR exercises that improve visual acuity, suppression and stereoacuity using adaptive algorithms to balance inputs to each eye.

AI strengths: Adaptive difficulty adjustments based on real-time patient performance, and automated session logging to support clinician monitoring and personalization.

Why choose Vivid Vision: Strong evidence base for VR-based amblyopia therapy and clinician-focused tools for monitoring remote therapy.

Luminopia — prescription digital therapeutics for pediatric amblyopia and adaptive content delivery

Overview: Luminopia develops digital therapeutic solutions that deliver targeted visual stimulation (often via streaming video mapped to therapeutic algorithms) to treat amblyopia and related pediatric conditions. Their product is designed to be used under clinician supervision.

Flagship offering: Luminopia Rx (and related therapeutic platforms) deliver content that selectively stimulates the amblyopic eye and adapts based on performance metrics.

AI strengths: Algorithms that adapt content delivery and difficulty to each patient’s response, plus analytics for remote monitoring by clinicians.

Why choose Luminopia: Clinically-oriented digital therapeutics that emphasize adherence, user engagement and remote monitoring.

Tobii — eye-tracking hardware and SDKs for therapy platform builders

Overview: Tobii is a global leader in eye-tracking hardware and software development kits (SDKs). While Tobii primarily supplies hardware components and developer tools, many therapy vendors build clinical products on Tobii components or integrate Tobii’s tracking into AI-driven therapy applications.

Flagship offering: Tobii Pro and Tobii Dynavox product lines provide high-fidelity eye trackers, SDKs and analytics suitable for research, clinical and assistive applications.

AI strengths: Precise gaze data enables downstream AI models to analyze oculomotor behavior, detect patterns, and drive adaptive therapy content.

Why choose Tobii: Extremely reliable tracking hardware and broad developer ecosystem that speeds productization for therapy startups and established device makers.

Notal Vision — home monitoring and AI triage for retinal disease (adjacent therapy/management use)

Overview: Notal Vision’s home OCT and monitoring platforms (e.g., ForeseeHome and Home OCT devices) are focused on early detection and monitoring of retinal disease like age-related macular degeneration (AMD). While primarily diagnostic/monitoring devices, they demonstrate the growing role of AI and remote devices in eye care management pathways that can complement therapeutic regimens.

Flagship offering: Notal Home OCT aims to detect disease activity earlier and route patients quickly to therapy when needed.

AI strengths: Automated image analysis and risk stratification models to prioritize clinical follow-up.

Why include Notal: Example of how AI-enabled home devices change therapy timing and patient management — useful for providers building integrated therapy+monitoring services.

Comparison table: Top AI-powered eye therapy manufacturers and suppliers

How to choose the right AI-powered eye therapy device supplier

Selecting a supplier should be based on clinical goals, deployment model and budget. Key considerations:

1. Clinical evidence and validation

Look for peer-reviewed studies, clinical trial data or published case-series demonstrating efficacy for the target condition (e.g., amblyopia, binocular dysfunction, post-concussion vision therapy). AI models should be explainable, validated on representative populations and, where applicable, evaluated against standard-of-care outcomes.

2. Regulatory and safety status

Verify regulatory status relevant to the US market: FDA clearance/approval, 510(k) listings, or a clear prescription pathway for software-as-a-medical-device (SaMD). If a device is marketed for wellness only, understand the limitations that places on clinical claims.

3. Integration & interoperability

Check how the device integrates with electronic health records (EHR), telehealth platforms and clinic workflows. Cloud-based platforms should support secure data transfer, HIPAA compliance and role-based access.

4. Support, training and service

Therapy programs require clinician and patient onboarding, remote monitoring tools and responsive technical support. Evaluate the supplier’s training materials, onboarding timelines and warranty/service agreements.

5. Pricing, reimbursement and ROI

Understand total cost: hardware, software licensing, maintenance and required consumables. For clinic buyers, model expected ROI based on increased throughput, remote-therapy revenue streams, or improved outcomes that reduce return visits.

Deployment scenarios and buyer profiles

Match vendors to typical buyer needs:

• Private optometry/ophthalmology clinics: Skaphor, RightEye, Vivid Vision — seek clinic-ready hardware + telemonitoring.
• Pediatric amblyopia programs & telehealth: Luminopia, Vivid Vision, Skaphor (with cloud) — emphasize adherence tools and parental engagement.
• Research institutions and device OEMs: Tobii for hardware & SDKs to build AI therapy prototypes or clinical studies.
• Integrated retina or chronic disease management programs: Notal Vision to link monitoring with timely therapeutic intervention.

Implementation checklist for clinics buying AI-powered eye therapy devices

• Confirm clinical indication and review supporting evidence for the target patient population.
• Ask for a live demo and request anonymized case reports or outcomes data from similar clinics.
• Verify data security, HIPAA compliance and whether the vendor will sign a Business Associate Agreement (BAA) if required.
• Confirm upgrade path and how AI model updates are handled (versioning, offline/online updates, clinical re-validation).
• Plan staff training, patient onboarding materials and a pilot period to measure outcomes and workflow impact.

Conclusion: Choose a vendor aligned to your clinical goals and infrastructure

AI-powered eye therapy devices are maturing rapidly. For US buyers, the right choice depends on clinical focus (pediatrics vs rehab vs retina monitoring), desired deployment model (clinic, home, hybrid) and evidence requirements. Skaphor (Guangzhou Ruiheng) offers full-stack hardware and cloud solutions suited for optical chains and clinics seeking scalable myopia and eye care programs; RightEye and Vivid Vision are strong choices for performance, binocular dysfunction and amblyopia therapy; Luminopia brings prescription digital therapeutics experience for pediatrics; Tobii serves as a best-in-class supplier of gaze hardware for developers; and Notal Vision shows how AI-enabled home monitoring complements therapy decisions. Use the decision checklist in this guide and request clinical data and demos before purchase.

Frequently Asked Questions

What is an AI-Powered Eye Therapy Device and how does it differ from traditional therapy?
An AI-Powered Eye Therapy Device uses machine learning or adaptive software to analyze user performance in real time, adjust therapy difficulty, predict outcomes, or monitor compliance. Unlike traditional static therapy (fixed exercises), AI-driven systems personalize therapy trajectories, provide objective progress metrics and support remote monitoring.

Are AI-powered eye therapy devices FDA cleared for use in the US?
Regulatory status varies by product. Some digital therapeutics and therapy-adjacent devices have cleared or are operating under regulated pathways; others are marketed for wellness or as clinician-directed tools. Always verify a product’s FDA 510(k) clearance or regulatory claims for the intended clinical use before purchase.

Can I deploy these devices for remote/home therapy?
Yes — several vendors (e.g., Vivid Vision, certain Skaphor cloud-enabled systems, Luminopia) support clinician-prescribed home therapy with remote monitoring. Ensure the vendor supports secure telemonitoring, adherence reporting and clinician dashboards.

How important is clinical evidence when choosing an AI-powered therapy device?
Clinical evidence is critical. Prefer vendors with peer-reviewed studies, clinical trials or validated case-series showing improved outcomes for the targeted condition. AI models must be validated on representative patient populations.

What support should vendors provide after purchase?
Ideal vendor support includes clinician and staff training, onboarding materials for patients, timely technical support, software updates with controlled validation, and clear maintenance or warranty terms.

Sources and further reading

• Skaphor (Guangzhou Ruiheng) — Company site: https://www.skaphor.net/ — retrieved 2025-12-28
• RightEye — Official site and product pages: https://www.righteye.com/ — retrieved 2025-12-28
• Vivid Vision — Official site and clinical information: https://www.vivid.vision/ — retrieved 2025-12-28
• Luminopia — Official site and product information: https://www.luminopiahealth.com/ — retrieved 2025-12-28
• Tobii — Eye tracking hardware and SDKs: https://www.tobii.com/ — retrieved 2025-12-28
• Notal Vision — Home OCT and monitoring platforms: https://www.notalvision.com/ — retrieved 2025-12-28
• Guidance on digital therapeutics and regulatory considerations: US FDA Digital Health Resources — https://www.fda.gov/medical-devices/digital-health — retrieved 2025-12-28